VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ILMNIllumina, Inc.
$175.09$26.6B
Research
OverviewAnalysis
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksILMNP/E History

ILMN logoIllumina, Inc. (ILMN) P/E Ratio History

Undervalued

Trading at 32.1x vs 5Y avg 56.3x · 20th percentile · Below historical baseline · Data 2006–2026

Current P/E (TTM)
32.1x
-43% vs 5Y avg
5Y Avg P/E
56.3x
Median 62.0x
5Y Percentile
20th
Lower end of range
PEG Ratio
7.59
Premium to growth
5-Year P/E Range
32.1x
Min12.0xMedian62.0xMax88.4x
TTM EPS$5.54
Price$175.09
Earnings Yield3.11%
EPS Growth (1Y)170.9%
EPS Growth (5Y)4.2%

Loading P/E history...

P/E Ratio Analysis

As of June 25, 2026, Illumina, Inc. (ILMN) trades at a price-to-earnings ratio of 32.1x, with a stock price of $175.09 and trailing twelve-month earnings per share of $5.54.

The current P/E is 43% below its 5-year average of 56.3x. Over the past five years, ILMN's P/E has ranged from a low of 12.0x to a high of 88.4x, placing the current valuation at the 20th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.5x, ILMN trades at a 43% premium to its sector peers. The sector includes 232 companies with P/E ratios ranging from 0.0x to 192.0x.

The PEG ratio of 7.59 (P/E divided by 171% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.

Relative to the broader market, ILMN commands a significant premium over the S&P 500 median P/E of 24.7x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ILMN DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

ILMN Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
32.1vs22.5
+43%
Above Sector
vs. S&P 500
32.1vs24.7
+30%
Above Market
PEG Analysis
7.59
P/E ÷ EPS Growth
PEG > 2 = Expensive
Based on 171% EPS growth (1Y)

ILMN P/E vs Peers

Life Science Instruments and Sequencing Tools peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
TMO logoTMOThermo Fisher Scientific Inc.
$183B27.713.14+7%
DHR logoDHRDanaher Corporation
$134B37.5--5%
A logoAAgilent Technologies, Inc.
$37B28.81.96Best+3%
BIO logoBIOBio-Rad Laboratories, Inc.
$8B10.0Lowest-+143%Best

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

ILMN Historical P/E Data (2006–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q1Mar 29 2026$117.67$5.5121.4x-70%
FY2025 Q4Dec 28 2025$134.95$5.4624.7x-66%
FY2025 Q3Sep 28 2025$91.69$4.4620.6x-71%
FY2025 Q2Jun 29 2025$94.79$7.9012.0x-83%
FY2022 Q1Apr 03 2022$353.65$4.5877.2x+7%
FY2021 Q4Dec 31 2021$369.72$5.0473.4x+2%
FY2021 Q3Oct 03 2021$383.72$6.0863.1x-12%
FY2021 Q2Jul 04 2021$461.36$5.2288.4x+23%
FY2021 Q1Apr 04 2021$374.19$4.2887.5x+21%
FY2020 Q4-$359.58$4.4580.8x+12%
FY2020 Q3Sep 27 2020$291.44$4.3167.5x-6%
FY2020 Q2Jun 28 2020$349.94$4.6874.7x+4%
FY2020 Q1Mar 29 2020$261.47$6.3541.1x-43%
FY2019 Q4-$322.40$6.7447.8x-34%
FY2019 Q3Sep 29 2019$292.79$6.5444.8x-38%
FY2019 Q2Jun 30 2019$357.78$6.3056.8x-21%
FY2019 Q1Mar 31 2019$301.94$5.7252.8x-27%
FY2018 Q4Dec 31 2018$291.48$5.5752.3x-27%
FY2018 Q3Sep 30 2018$356.72$4.6277.2x+7%
FY2018 Q2Jul 01 2018$271.42$4.3862.0x-14%
FY2018 Q1Apr 01 2018$229.76$3.8459.8x-17%
FY2017 Q4Dec 31 2017$212.34$4.9742.7x-41%
FY2017 Q3Oct 01 2017$193.59$5.3536.2x-50%
FY2017 Q2Jul 02 2017$168.63$5.1232.9x-54%
FY2017 Q1Apr 02 2017$165.83$5.0632.8x-55%
FY2016 Q4Dec 31 2016$124.43$3.1339.8x-45%
FY2016 Q3Oct 02 2016$176.54$2.9959.0x-18%
FY2016 Q2Jul 03 2016$136.77$2.9147.0x-35%
FY2016 Q1Apr 03 2016$162.16$2.7958.1x-19%
FY2015 Q4-$186.54$3.1060.2x-17%
FY2015 Q3Sep 27 2015$170.60$3.4349.7x-31%
FY2015 Q2Jun 28 2015$211.92$3.2764.8x-10%
FY2015 Q1Mar 29 2015$181.90$2.8962.9x-13%
FY2014 Q4Dec 31 2014$179.38$2.3775.7x+5%
FY2014 Q3Sep 28 2014$160.78$1.9084.6x+17%
FY2014 Q2Jun 29 2014$167.84$1.49112.6x+56%
FY2014 Q1Mar 30 2014$138.02$1.4495.8x+33%
FY2013 Q4-$107.48$0.86125.0x+73%
FY2013 Q3Sep 29 2013$78.73$0.8394.9x+32%
FY2013 Q2Jun 30 2013$72.73$0.8387.6x+22%
FY2013 Q1Mar 31 2013$52.46$0.7569.9x-3%
FY2012 Q4Dec 31 2012$54.02$1.1347.8x-34%
FY2012 Q3Sep 30 2012$46.83$0.6967.5x-6%
FY2012 Q2Jul 01 2012$39.25$0.6262.9x-13%
FY2012 Q1Apr 01 2012$51.13$0.6677.0x+7%
FY2011 Q4Dec 31 2011$29.62$0.6247.5x-34%
FY2011 Q3Oct 02 2011$39.77$0.7851.0x-29%
FY2011 Q2Jul 03 2011$73.87$0.8784.9x+18%
FY2011 Q1Apr 03 2011$68.77$0.8680.0x+11%
FY2010 Q4Dec 31 2010$61.56$0.8671.6x-1%
FY2010 Q3Oct 03 2010$47.71$0.7068.5x-5%
FY2010 Q2Jul 04 2010$41.88$0.5872.7x+1%
FY2010 Q1Apr 04 2010$38.19$0.5569.9x-3%
FY2009 Q4-$29.82$0.5356.7x-21%
FY2009 Q3Sep 27 2009$39.51$0.6659.9x-17%
FY2009 Q2Jun 28 2009$37.09$0.4877.4x+7%
FY2009 Q1Mar 29 2009$36.17$0.4286.3x+20%
FY2008 Q4Dec 31 2008$25.32$0.3965.1x-10%
FY2008 Q3Sep 28 2008$41.21$0.13311.5x+332%
FY2008 Q2Jun 29 2008$42.17$0.31134.6x+87%
FY2008 Q1Mar 30 2008$36.10$0.27132.2x+83%
FY2006 Q4Dec 31 2006$19.10$0.4047.7x-34%
FY2006 Q3Oct 01 2006$16.05$0.2368.6x-5%
FY2006 Q2Jul 02 2006$14.41$0.06255.5x+254%

Average P/E for displayed period: 72.1x

Export Data
Consensus-Based Analysis Tools

Full Stock Analysis

Deep dive into ILMN consensus models and risk factors.

View Analysis

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

20+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ILMN — Frequently Asked Questions

Quick answers to the most common questions about buying ILMN stock.

What is ILMN's P/E ratio?

Illumina, Inc. (ILMN) trailing twelve-month P/E ratio is 32.1x, based on TTM diluted EPS of $5.54. The 5-year average P/E is 56.3x and the historical range spans 12.0x to 88.4x.

Is ILMN stock overvalued or undervalued?

ILMN trades at 32.1x P/E, below its 5-year average of 56.3x. At the 20th percentile of its historical range (12.0x–88.4x), the stock is priced at a discount to its own history.

Is ILMN stock expensive?

No, ILMN is not expensive on a historical basis. The current P/E of 32.1x is below the 5-year average of 56.3x and sits at the 20th percentile of its valuation range.

What is ILMN's historical P/E range?

Over the past 5 years, ILMN's P/E ratio has ranged from 12.0x to 88.4x, with a median of 62.0x and an average of 56.3x. The current P/E of 32.1x places the stock at the 20th percentile of this range. Full historical data spans 2006–2026.

How does ILMN's P/E compare to the S&P 500?

ILMN trades at 32.1x P/E versus the S&P 500 median of 24.7x. The 30% premium to the market typically reflects higher expected earnings growth or quality.

How does ILMN's valuation compare to Healthcare peers?

Illumina, Inc. P/E of 32.1x compares to the Healthcare sector median of 22.5x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is ILMN's PEG ratio?

ILMN PEG ratio is 7.59, based on a P/E of 32.1x and EPS growth of 170.9%. A PEG above 2.0 indicates a premium valuation relative to earnings growth — typically considered expensive.

What is ILMN's earnings yield?

ILMN earnings yield is 3.11%, the inverse of its 32.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

ILMN P/E Ratio History (2006–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current21.4x
Period Avg56.3x
Range12.0x - 88.4x
Change-66%
20 quartersJul 1, 2018 - Mar 29, 2026